Presented at ASCO data on the first set of patients from the pivotal Phase III TK008 study: the survival benefit exceeds trial target in acute leukaemia patients.
MolMed announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial (TK008) of its proprietary TK cell/gene therapy for high-risk leukaemia patients.
MolMed S.p.A. will present further data on the efficacy of the investigational drug NGR-hTNF in soft tissues sarcomas tomorrow at the European Cancer Congress.
MolMed Shareholders' Meeting confirms the appointment of a Member of the Board and approves Measures to be adopted pursuant to Article 2446 of the Italian Civil Code.
MolMed S.p.A. (MLM.MI) announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta (GA, U.S.).
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2012.
Satisfied Users & 
Approved Press Releases
